A sociodemographic study to evaluate the pattern of adverse drug reaction with new inactive or injectable polio vaccine and awareness about ipv

The introduction of one dose of IPV into routine immunization programme is to mitigate risks associated with OPV withdrawal and potential reintroduction of poliovirus. In polio Eradication and End Game Strategic Plan, SAGE (Strategic Advisory Group Of Experts) on Immunization has recommended that all OPV using countries should introduce one dose of IPV into routine immunization schedule and administer that dose at or >14 weeks of age in addition to the 3 to 4 doses of OPV in primary series. India has incorporated IPV under National Immunization Programme in November 2015. Our study focused on awareness about IPV among people and health care workers. We carried out this study to collect sociodemographic profile for monitoring use, and coverage of IPV, to identify the pattern of adverse drug effects with new IPV, to assess the knowledge and awareness about IPV in society. Though our study showed that with 97.7 to 100 % coverage of immunization with IPV, only minor local complaints after IPV administration but no single adverse events reported or documented either by the parent or by the health care persons. Our study information is useful to find how effectively immunization targets have met and -how efficiently the IPV is being used. Detected adverse drug reactions with IPV would be helpful -to maintain Universal Immunization Programme. This pilot project was undertaken with provision of use of IPV in routine and campaigns to assess vaccine acceptance to support country policy decisions; and ecologic studies in developing countries switching to all-IPV routine immunization schedules to evaluate potential emergence of cVDPVs and risk of WPV importations.